Johnson & Johnson (JNJ) Earnings Call Transcripts
Johnson & Johnson's Latest Earnings Call - September 17, 2026
In the Q3 2026 earnings call, Johnson & Johnson (JNJ:US) reported a revenue increase of 6.6% year-over-year, signaling strong performance driven by their Innovative Medicines segment, which now represents two-thirds of total sales. The company raised its fiscal year 2026 sales outlook to exceed $100 billion, with management expressing confidence in achieving a long-term growth rate of 5% to 7%, and even a potential for double-digit growth in the coming years. Earnings guidance remains stable, with a projected free cash flow of approximately $21 billion for 2026, indicating robust operational efficiency and cash generation capabilities.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $100B+ (beat) |
| Q3 Revenue Growth | 6.6% (beat) |
| Free Cash Flow | $21B (beat) |
| Long-term Growth Rate Guidance | 5% to 7% (inline) |
| Market Share in Oncology | $50B (positive) |
| Product Launch Growth (Icotide) | 80% growth in Q2 (positive) |
Guidance from management
Management maintained a long-term growth rate guidance of 5% to 7% and expressed confidence in achieving double-digit growth in the coming years. Free cash flow is projected to reach $21 billion in 2026, supporting ongoing investments and shareholder returns.
What management said
As long as I've been with the company, I think it's always kind of been a 50-50 split 48-52, -- it's a little ambiguous now with some of the MFN deals and pharmaceuticals and how that may play out. We certainly do need to see, particularly Europe, I think, step into reimbursing for quite frankly, innovations that are highly valued that extend and improve lives significantly. So it's hard to say that, but I wouldn't s...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape in medtech, particularly with new entrants in electrophysiology and IVL markets. There is also apprehension about the potential impact of ongoing legal issues on the company's financial stability.
Main topics on the call
- Revenue Growth and Guidance — Johnson & Johnson reported a revenue increase of 6.6% in Q3 2026, raising its fiscal year sales outlook to exceed $100 billion. CFO Joseph Wolk stated, "We see double digits, a clear line of sight to double digits for th...
- Pharmaceuticals and MedTech Balance — Management emphasized the importance of maintaining a balanced portfolio between pharmaceuticals and medtech, with pharmaceuticals currently driving higher growth. Wolk noted, "We want to make sure... we're playing in hi...
- Product Launch Success — The company highlighted the successful launch of icotide for psoriasis, which is expected to expand into IBD indications. Wolk mentioned, "We should see a number of more to that," indicating potential for higher sales th...
- M&A Strategy — Management reiterated a disciplined approach to M&A, focusing on strategic fit rather than immediate financial pressures. Wolk stated, "I never have to go out and do a bad deal just to plug a gap," emphasizing their long...
Read the full Johnson & Johnson transcript (September 17, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Johnson & Johnson
Johnson & Johnson (JNJ) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 122 calls on record spanning January 13, 2020 to September 17, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 122 Johnson & Johnson earnings call transcripts on record, spanning January 13, 2020 to September 17, 2026. Based on this history, Johnson & Johnson reports quarterly. The most recent call on file is dated September 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- JNJ
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 122
- First call
- January 13, 2020
- Most recent
- September 17, 2026
- Reporting cadence
- quarterly